China chip stocks fall as US considers allowing Nvidia H200 sales
OAK RIDGE, Tenn. - Daxor Corporation (NASDAQ:DXR), a niche player in medical diagnostics with a market capitalization of $58.62 million, will exhibit its newly FDA-cleared next-generation blood volume analyzer (BVA) at the Heart Failure Society of America Annual Scientific Meeting in Minneapolis from September 26-29, 2025, according to a company press release. The company's stock has shown remarkable momentum, surging 41% over the past six months and trading near its 52-week high of $11.90. According to InvestingPro analysis, the stock appears to be trading above its Fair Value, though analyst targets suggest potential upside with price targets ranging from $22 to $25.
The new device represents a significant technological advancement over its predecessor, the BVA-100. The system operates three times faster, requires 50% less blood to be drawn from patients, and maintains over 95% accuracy while being lighter and battery-operated. For investors tracking healthcare innovation, InvestingPro offers comprehensive analysis of 1,400+ healthcare companies, including detailed Pro Research Reports that transform complex financial data into actionable intelligence.
"The recent FDA clearance for our new BVA system is a significant milestone that we are excited to share with the heart failure community," said John L. Jefferies, MD, MPH, MBA, Daxor's Chief Medical Officer.
During the conference, Daxor's clinical partners will present new data validating the BVA technology. Presentations include an oral abstract from Wellstar Health System on reducing renal replacement therapy in advanced heart failure patients undergoing LVAD implantation, and an e-poster from Banner University Medical Center examining the impact of normal intravascular blood volumes in heart failure patients.
Jonathan Feldschuh, Daxor's Chief Scientific Officer, stated that the new analyzer demonstrates how "groundbreaking science can be simplified without sacrificing precision."
The company will participate in Device Day at the conference and exhibit at Booth #1007 during the main meeting.
Daxor's blood volume measurement technology aims to provide clinicians with precise data to guide individualized treatment decisions for conditions including heart failure and those requiring intensive care unit management.
In other recent news, Daxor Corporation has received FDA 510(k) clearance for its next-generation blood volume analyzer, a compact and portable device intended for laboratory use. This hand-held analyzer measures a patient's blood volume against specific norms, offering critical data for fluid management in various clinical conditions. The device is noted for being three times faster than its predecessor while maintaining laboratory-grade precision, and it weighs just 7 pounds. Additionally, Daxor held its annual meeting of shareholders, where six directors were elected to serve until the next annual meeting. The directors elected include Henry D. Cremisi, MD; Edward Feuer; Joy Goudie, Esq.; Michael Feldschuh; Jonathan Feldschuh; and Caleb DesRosiers, Esq. The company also ratified its auditor during this meeting. These developments mark significant progress for Daxor in both product innovation and corporate governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.